Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

21.0K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
21.0K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

859
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
859
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

527
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
527
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

725
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
725
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

518
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
518
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

550
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
550

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Men with subjective premature ejaculation have a similar lognormal IELT distribution as men in the general male population and differ mathematically from males with lifelong premature ejaculation after an IELT of 1.5 minutes (Part 2).

International journal of impotence research·2019
Same author

Use of a confirmed mathematical method for back-analysis of IELT distributions: ejaculation time differences between two continents and between continents and men with lifelong premature ejaculation (Part 1).

International journal of impotence research·2019
Same author

Differences between ICD-11 MMS and DSM-5 definition of premature ejaculation: a continuation of historical inadequacies and a source of serious misinterpretation by some European Regulatory Agencies (PART 2).

International journal of impotence research·2019
Same author

Method and design of drug treatment research of subjective premature ejaculation in men differs from that of lifelong premature ejaculation in males: proposal for a new objective measure (part 1).

International journal of impotence research·2019
Same author

Tramadol's Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.

Frontiers in pharmacology·2018
Same author

Restless Genital Syndrome (ReGS) Should Be Distinguished From Spontaneous Orgasms: A Case Report of Cannabis-Induced Spontaneous Orgasm.

Journal of sex & marital therapy·2017

Related Experiment Video

Updated: Feb 7, 2026

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

2.6K

Drug treatment options for premature ejaculation.

Marcel D Waldinger1,2,3

  • 1a Department of Pharmacology and Physiology , Drexel University College of Medicine , Philadelphia , PA , USA.

Expert Opinion on Pharmacotherapy
|July 21, 2018
PubMed
Summary

This review examines premature ejaculation (PE) pharmacotherapy, highlighting registered drugs like dapoxetine and Fortacin™. It also addresses over-the-counter products for subjective PE, emphasizing the need for evidence-based recommendations and further research.

Keywords:
Fortacin TMPremature ejaculationPromescentSSRIsStud-100clomipraminedapoxetine

More Related Videos

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

10.0K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.8K

Related Experiment Videos

Last Updated: Feb 7, 2026

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

2.6K
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

10.0K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.8K

Area of Science:

  • Pharmacology
  • Urology
  • Sexual Medicine

Background:

  • Premature ejaculation (PE) has various treatment options, but only dapoxetine and Fortacin™ are officially registered.
  • Men with subjective PE often use uninvestigated over-the-counter products.
  • A critical review of registered and non-registered PE drugs is needed.

Purpose of the Study:

  • To provide evidence-based recommendations for PE pharmacotherapy based on International Society of Sexual Medicine (ISSM) guidelines.
  • To review current registered and non-registered drug treatments for lifelong and acquired PE.
  • To discuss the challenges in drug development for subjective PE.

Main Methods:

  • Literature review adhering to ISSM guidelines for PE treatment.
  • Analysis of pharmacotherapy for lifelong and acquired PE.
  • Discussion of drug registration requirements and study designs for subjective PE.

Main Results:

  • Dapoxetine and Fortacin™ are the only registered drugs for PE.
  • Psychoeducation, counseling, and side effect information are crucial adjuncts to pharmacotherapy.
  • Current drug registration processes may hinder the development of treatments for subjective PE.

Conclusions:

  • Evidence-based recommendations for PE pharmacotherapy are essential.
  • Further research and specific drug development are needed for subjective PE.
  • Official recognition of subjective PE as a distinct subtype could facilitate targeted drug development.